Abstract

The More Medicines for Tuberculosis (MM4TB) consortium evolved from the highly successful FP6 project, New Medicines for TB (NM4TB), which delivered a candidate drug for clinical development two years ahead of schedule. Building on these firm foundations and exploiting its proprietary pharmacophores, MM4TB will continue to develop new drugs for TB treatment.

Mission

The MM4TB research consortium has been assembled to discover anti-infective agents that will combat TB. Evolved from the FP6 project, New Medicines for TB (NM4TB) - which successfully delivered a candidate drug for clinical development two years ahead of schedule - the MM4TB team will apply an integrated approach that includes tripartite screening strategies and medicinal chemistry,
functional genomics and structural biology. This combination of approaches is a broad strategy to discover new compounds, perform pharmacological validation, identify targets, and analyze a variety of mechanisms of action during Mycobacterium tuberculosis (M. tb) infection.

Consortium History

The consortium’s original project was titled New Medicines for TB (NM4TB), which successfully discovered the benzothiazinone (BTZ) series, now in late stage preclinical development. Now, MM4TB seeks to discover more anti-infective agents that will combat TB.

Structure & Governance

The consortium is overseen by the European Commission’s 7th Framework Programme

Financing

Funding for MM4TB is made available by the European Commission’s 7th Framework Programme

Impact/Accomplishment

A resource list of MM4TB publications can be found on their website under the “Publications” tab.

Links/Social Media Feed

Homepage http://www.mm4tb.org/
Points of Contact

ECOLE POLYTECHNIQUE FEDERALE DE LAUSANNE
BATIMENT CE 3316 STATION 1
1015 LAUSANNE
Switzerland
Activity type: Higher or Secondary Education Establishments
Administrative contact: Stewart Cole
Tel.: +41216931851
Fax: +41216931790

Sponsors & Partners

The École Polytechnique Fédérale de Lausanne (EPFL)
AstraZeneca
Sanofi-aventis
Alere
Vichem
Cellworks
CDD
Tydock
Uppsala University
Pavia University
University of Cambridge
Queen Mary’s University
University of London
Padova University
Comenius University
Piemonte Oreintale University
Basque Country University
University of Zaragoza
ETH Zurich University